Our flexible approach and in-house expertise across the research and development pipeline, coupled with an unwavering commitment to delivering better treatments, make us the ideal partner.
We partner with organisations from around the globe to work towards our ultimate ambition: to find a cure and bring forward the day when no one fears Parkinson's.
How we can help
We have the skills and resources to add value to your project, whether you're in the initial stages of drug discovery, gearing up to start clinical development or entering phase 3.
The Parkinson's Virtual Biotech is the drug discovery and development arm of Parkinson's UK.
We invest in projects and companies that are driving towards new treatments with the potential to transform the lives of people with Parkinson's.
We select and support projects at the drug discovery, preclinical and early clinical development stages.
Our virtual approach means we work flexibly and creatively with pharmaceutical companies and biotechs worldwide to develop and commercialise new treatments.
We are building a portfolio of projects that can attract further investment, and we’ll look to partner with companies to take successful projects into the later stages of drug development and trials.
Our Take Part Hub connects potential participants to the right trial for them.
In 2017 alone, we helped 60 research studies and trials to find participants to time and target, and we can help you do the same.
In the longer term, we need to make trials faster, smarter and more likely to succeed.
The Critical Path for Parkinson's is an international collaboration, funded and led by Parkinson’s UK. This brings together companies, regulatory agencies, universities and charities to create new tools and strategies to improve clinical trials for Parkinson's, and we welcome more members to join this crucial initiative.
We work in partnership with people with Parkinson's and their families to ensure research is shaped and driven by those who need it most.
To develop truly transformational new treatments we must listen to and involve patients at every stage of the research process.
As the world's largest patient-led Parkinson's charity, we are experts in bringing researchers and people with the condition together.
We advise companies on the best strategies for involving people in research development programmes and through our unique patient network, we can help you find the right individuals to help you achieve meaningful outcomes.